XBiotech Inc
XBIT
Company Profile
Business description
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
88
Stocks News & Analysis
stocks
Looking for growth outside the ASX100
Small caps have outperformed blue chips this year. Here’s some opportunities outside the ASX100.
stocks
Netflix and Warner Bros. Discovery: Surprisingly high merger price alters shareholder value for both
Our view on the blockbuster merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.00 | 26.10 | 0.29% |
| CAC 40 | 8,104.48 | 10.26 | -0.13% |
| DAX 40 | 24,080.61 | 52.47 | 0.22% |
| Dow JONES (US) | 47,954.99 | 104.05 | 0.22% |
| FTSE 100 | 9,669.64 | 2.63 | 0.03% |
| HKSE | 25,765.36 | 319.72 | -1.23% |
| NASDAQ | 23,578.13 | 72.99 | 0.31% |
| Nikkei 225 | 50,581.94 | 90.07 | 0.18% |
| NZX 50 Index | 13,486.32 | 2.33 | 0.02% |
| S&P 500 | 6,870.40 | 13.28 | 0.19% |
| S&P/ASX 200 | 8,624.40 | 28.80 | 0.34% |
| SSE Composite Index | 3,924.08 | 21.27 | 0.55% |